BioSante Pharmaceuticals to Present at J.M. Dutton Health Sciences Conference.

Business Editors/Health/Medical Writers

BIOWIRE2K

J.M. Dutton Health Sciences Conference

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jan. 15, 2004

BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today that its president and chief executive officer Stephen M. Simes will present at J.M. Dutton's Health Sciences Conference in San Francisco on January 22, 2004 at 1 p.m. EST. The audio webcast will be available live, then archived for 90 days at: www.friedlandcapitalevents.com/Webcast.htm.

This J.M. Dutton conference will bring together publicly-traded companies in the pharmaceutical and biotechnology industries. During his presentation Mr. Simes will discuss BioSante's hormone therapy products and nanotechnology

being developed for improved vaccines and drug delivery. Attendees at the conference will be key members of the investment community including portfolio managers, analysts, brokers and investment bankers.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for topical administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales. BioSante also is developing its nanotechnology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins, such as insulin. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference.